Korean J Urol Oncol.
2016 Dec;14(3):109-117. 10.22465/kjuo.2016.14.3.109.
Recombinant Bacille Calmette–Guérin for Immunotherapy in Nonmuscle Invasive Bladder Cancer
- Affiliations
-
- 1Department of Urology, Chung-Ang University Hospital, Seoul, Korea. caucih@cau.ac.kr
- KMID: 2368943
- DOI: http://doi.org/10.22465/kjuo.2016.14.3.109
Abstract
- Intravesical instillation of Mycobacterium bovis bacille Calmette-Guérin (BCG) has been used for treating nonmuscle invasive bladder cancer as the forefront of immunotherapy, but BCG is ineffective in approximately 30-40% of cases and disease recurs in up to 50% of patients. Recently BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, and the genetic control of these mycobacteria is advanced in the search for less toxic and more potent therapeutic agents for bladder cancer immunotherapy. We will discuss current advances in recombinant BCG construction, research, and future directions.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Tuberculous Prostatic Abscess with Prostatorectal Fistula after Intravesical Bacillus Calmette-Guérin Immunotherapy
- Bacillus Calmette-Guérin (BCG)-Cell Wall Skeleton as Immunotherapeutic Option for BCG-Refractory Superficial Bladder Cancer
- Tuberculous Prostatic Abscess Following Intravesical Bacillus Calmette-Guerin Instillation
- Predictive Molecular and Protein Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer
- Treatment Case of Asymptomatic Prostate Tuberculosis That Developed After Bacillus Calmette-Guerin Intravesical Therapy in a Patient With Nonmuscle Invasive Bladder Cancer
